GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 233 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $7,394,000 | -44.4% | 231,435 | -39.7% | 0.36% | -32.6% |
| Q1 2022 | $13,293,000 | +20.9% | 383,752 | +2.2% | 0.53% | +35.9% |
| Q4 2021 | $10,991,000 | +5.3% | 375,518 | -8.4% | 0.39% | +1.0% |
| Q3 2021 | $10,441,000 | -14.5% | 409,781 | +17.5% | 0.39% | -11.1% |
| Q2 2021 | $12,209,000 | -25.0% | 348,619 | -12.7% | 0.43% | -18.1% |
| Q1 2021 | $16,272,000 | -4.5% | 399,305 | +1.5% | 0.53% | -11.7% |
| Q4 2020 | $17,039,000 | -3.7% | 393,415 | +22.6% | 0.60% | -15.8% |
| Q3 2020 | $17,696,000 | +17.0% | 320,927 | +33.9% | 0.71% | +9.9% |
| Q2 2020 | $15,126,000 | +33.2% | 239,607 | +7.8% | 0.65% | +2.2% |
| Q1 2020 | $11,355,000 | -37.9% | 222,255 | -3.3% | 0.64% | +2.8% |
| Q4 2019 | $18,271,000 | +59.7% | 229,852 | -2.5% | 0.62% | +51.1% |
| Q3 2019 | $11,439,000 | +56.3% | 235,762 | +69.5% | 0.41% | +68.3% |
| Q2 2019 | $7,318,000 | – | 139,120 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |